Having -c(=x)-x-, Wherein The Xs Are The Same Or Diverse Chalcogens, Attached Indirectly To The Diazole Ring By Acyclic Nonionic Bonding Patents (Class 548/308.7)
-
Patent number: 10370339Abstract: The present invention relates to benzimidazol-2-amines of general formula (I), in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.Type: GrantFiled: June 3, 2016Date of Patent: August 6, 2019Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Sven Ring, Olaf Panknin, Katja Zimmermann, Judith Günther, Lars Bärfacker
-
Patent number: 9012481Abstract: Novel benzoarylureido compounds and a use thereof for prevention and/or treatment of the neurodegenerative brain disease are provided. The neurodegenerative brain diseases may include Alzheimer's disease, dementia, Parkinson's disease, stroke, amyloidosis, Pick's disease, Lou Gehrig's disease, Huntington's disease, Creutzfeld-Jakob disease, and the like.Type: GrantFiled: December 29, 2009Date of Patent: April 21, 2015Assignee: Korea Institute of Science and TechnologyInventors: Hoh-Gyu Hahn, Kee-Dal Nam, Dong-Yun Shin, Chan-Ho Park, Sung-Woo Cho, Eun-A Kim, Ghil-Soo Nam, Kyung-Il Chol, Seon-Hee Seo, Hee-Sup Shin, Dong-Jin Kim, Ae-Nim Pae, Hye-Jin Chung, Hyun-Ah Choo, Hye-Whon Rhim, Yong-Seo Cho, Eun-Joo Roh, Gyo-Chang Keum, Kee-Hyun Choi, Kye-Jung Shin, Chan-Seong Cheong, Jae-Kyun Lee, Yong-Koo Kang, Young-Soo Kim, Woong-Seo Park, Key-Sun Kim, He-Sson Chung, Chi-Man Song, Sun-Joon Min, Eunice Eun-Kyeong Kim, Cheol-Ju Lee, Soon-Bang Kang
-
Patent number: 8916599Abstract: There are provided compounds of formula (I), wherein R1, R6, R8, Q2, Q3, Q3a, Q4, L and A have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation and/or cancer.Type: GrantFiled: September 25, 2009Date of Patent: December 23, 2014Assignee: Orexo ABInventors: Roland Pfau, Kirsten Arndt, Henri Doods, Norbert Hauel, Klaus Klinder, Raimund Kuelzer, Juergen Mack, Henning Priepke, Dirk Stenkamp
-
Publication number: 20140228378Abstract: The invention provides novel substituted cyclopropane carboxamide compounds according to Formula (I), their manufacture and use for the treatment of proliferative or inflammatory diseases, such as cancer, fibrosis or arthritis.Type: ApplicationFiled: July 7, 2012Publication date: August 14, 2014Applicant: MERCK PATENT GMBHInventors: Wolfgang Staehle, Melanie Schultz, Kai Schiemann
-
Publication number: 20120202840Abstract: Provided are methods for treating a hematological malignancy comprising administering an effective amount of flubendazole alone or in combination with a vinca alkaloid. Also provided are compositions and kits comprising an effective amount of flubendazole and/or a vinca alkaloid for use in the methods of the disclosure.Type: ApplicationFiled: October 8, 2010Publication date: August 9, 2012Applicant: UNIVERSITY HEALTH NETWORKInventors: Aaron David Schimmer, Jiayi Hu, Paul Anthony Spangnuolo
-
Publication number: 20110319456Abstract: Novel benzoarylureido compounds and a use thereof for prevention and/or treatment of the neurodegenerative brain disease are provided. The neurodegenerative brain diseases may include Alzheimer's disease, dementia, Parkinson's disease, stroke, amyloidosis, Pick's disease, Lou Gehrig's disease, Huntington's disease, Creutzfeld-Jakob disease, and the like.Type: ApplicationFiled: December 29, 2009Publication date: December 29, 2011Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Hoh-Gyu Hahn, Kee-Dal Nam, Dong-Yun Shin, Chan-Ho Park, Sung-Woo Cho, Eun-A Kim, Ghil-Soo Nam, Kyung-Il Chol, Seon-Hee Seo, Hee-Sup Shin, Dong-JIn Kim, Ae-Nim Pae, Hye-JIn Chung, Hyun-Ah Choo, Hye-Whon Rhim, Yong-Seo Cho, Eun-Jon Roh, Gyo-Chang Keum, Kee-Hyun Choi, Kye-Jung Shin, Chan-Seong Cheong, Jae-Kyun Lee, Yong-Koo Kang, Young-Soo Kim, Woong-Seo Park, Key-Sun Kim, He-Sson Chung, Chi-Man Song, Sun-Joon Min, Eunlce Eun-Kyeong Kim, Cheol-Ju Lee, Soon-Bang Kang
-
Publication number: 20110312969Abstract: Compounds of general formula (I): wherein R1, R2, R3, R4, R5, R6, X and Y are as defined herein are inhibitors of Bcl-2 and are useful for treating diseases characterised by abnormal cell growth and/or dysregulated apoptosis.Type: ApplicationFiled: December 8, 2009Publication date: December 22, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Stephen Peter East, Mark Whittaker, Osamu Ichihara, Adrian Kotei Kotei, Smantha Jayne Bamford
-
Patent number: 8076366Abstract: Novel polymorphic forms of bendamustine free base are described, including amorphous bendamustine free base, six anhydrous crystalline forms, four hydrate forms, and five solvate forms, with methods of their preparation and use also being described.Type: GrantFiled: January 14, 2010Date of Patent: December 13, 2011Assignee: Cephalon, Inc.Inventors: Laurent D. Courvoisier, Mark Eddleston, R. Curtis Haltiwanger, Robert E. McKean
-
Publication number: 20110176998Abstract: The present invention features compositions and methods for detecting, selecting a treatment method for, monitoring, and treating a neoplasia associated with a viral infection.Type: ApplicationFiled: October 13, 2010Publication date: July 21, 2011Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Martin G. Pomper, Richard Ambinder, Jun O. Liu, Curtis R. Chong, Jianmeng Chen
-
Patent number: 7910594Abstract: This invention relates to vitamin-mitomycin conjugates, to a method of using the conjugates to selectively eliminate a population of pathogenic cells in a host animal harboring the pathogenic cells, and to a method of preparation of the conjugates. The conjugate is of the general formula B-L-X wherein the group B is a vitamin, or an analog or a derivative thereof, that binds to a surface accessible vitamin receptor that is uniquely expressed, overexpressed, or preferentially expressed by a population of pathogenic cells, wherein the group L comprises a cleavable linker, and wherein the group X comprises a mitomycin compound, or an analog or a derivative thereof. An additional therapeutic agent, such as a chemotherapeutic agent, can be administered in combination with the conjugate.Type: GrantFiled: May 13, 2003Date of Patent: March 22, 2011Assignee: Endocyte, Inc.Inventors: Iontcho Radoslavov Vlahov, Christopher P. Leamon
-
Publication number: 20110034528Abstract: The present invention describes Elansolids, a new class of novel anti-bacterial compounds of formula (I).Type: ApplicationFiled: February 19, 2009Publication date: February 10, 2011Inventors: Klaus Gerth, Heinrich Steinmetz, Gerhard Höfle
-
Publication number: 20100210701Abstract: Novel polymorphic forms of bendamustine free base are described, including amorphous bendamustine free base, six anhydrous crystalline forms, four hydrate forms, and five solvate forms, with methods of their preparation and use also being described.Type: ApplicationFiled: January 14, 2010Publication date: August 19, 2010Applicant: CEPHALON, INC.Inventors: Laurent D. Courvoisier, Mark Eddleston, R. Curtis Haltiwanger, Robert E. McKean
-
Patent number: 7452912Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.Type: GrantFiled: December 11, 2002Date of Patent: November 18, 2008Assignees: Elan Pharmaceuticals, Inc., WyethInventors: Francine S. Grant, Andrei W. Konradi, Michael A. Pleiss, Eugene D. Thorsett
-
Patent number: 7205412Abstract: An antibiotic additive and an ink composition including the antibiotic additive include a compound produced by binding of an antibiotic substance having the following formula (I) to a predetermined additive via a chemical reaction. The ink composition includes a colorant, a solvent and an antibiotic additive produced by binding of an antibiotic substance having the following formula (I) to a predetermined additive via a chemical reaction.Type: GrantFiled: July 2, 2003Date of Patent: April 17, 2007Assignee: Samsung Electronics Co., Ltd.Inventors: Seung-min Ryu, Jae-hwan Kim, Jong In Lee, Dae hee Lee
-
Patent number: 6875765Abstract: The novel arylsulfonamide ether compounds, pharmaceutical compositions and uses thereof as inhibitors of interleukin-1? converting enzyme and other cysteine proteases in the ICE family are described. In one embodiment, the compound is described by the generalized structure: and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof. In addition, methods of treating stroke, inflammatory diseases, septic shock, repurfusion injury, Alzheimer's disease, and shigellosis, using a compound of the invention or a pharmaceutical composition thereof, are described.Type: GrantFiled: May 10, 2002Date of Patent: April 5, 2005Assignee: Warner-Lambert CompanyInventors: James Knobelsdorf, Sheryl Hays, Charles J. Stankovic, Kimberly S. Para, Michael K. Connolly, Paul Galatsis, William Harter, Aurash B. Shahripour, Mark Stephen Plummer, Beth Lunney, Bernd Janssen, Jay Bradford Fell
-
Publication number: 20040116710Abstract: Disclosed are compounds of the formula I 1Type: ApplicationFiled: August 29, 2003Publication date: June 17, 2004Inventors: Eli M. Wallace, Joseph P. Lyssikatos, Allison L. Marlow, T. Brian Hurley, Kevin Koch
-
Patent number: 6720349Abstract: Benzimidazole derivatives and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compounds. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.Type: GrantFiled: April 25, 2002Date of Patent: April 13, 2004Assignee: UAF Technologies and Research, LLCInventors: James C. Quada, Jr., Joseph K. Agyin, James Berger Camden
-
Patent number: 6677360Abstract: The present invention relates to biphenyl and biphenyl-analogous compounds, their preparation and use as pharmaceutical compositions, as integrin antagonists and in particular for the production of pharmaceutical compositions for the treatment and prophylaxis of cancer, arteriosclerosis, restenosis, osteolytic disorders such as osteoporosis and ophthalmic diseases. The compounds according to the invention have the formula (1) wherein R1, R2, U, V, A, B, W, R3, C and R4 have the meaning as defined in the claims.Type: GrantFiled: April 6, 2001Date of Patent: January 13, 2004Assignee: Bayer AktiengesellschaftInventors: Markus Albers, Klaus Urbahns, Andrea Vaupel, Michael Härter, Delf Schmidt, Beatrix Stelte-Ludwig, Christoph Gerdes, Elke Stahl, Jörg Keldenich, Ulf Brueggemeier, Klemens Lustig
-
Patent number: 6645950Abstract: Vascular damaging agents composed of substituted 5(6)-substituted benzimidazole-2-carbamates are provided. These agents are useful in the preparation of medicaments for the treatment of diseases involving neovascularisation, particularly for the treatment of solid tumors, macular degeneration, diabetic retinopathy, rheumatoid arthritis, psoriasis, and atherosclerosis. Embodiments include a 5(6)-substituted benzimidazole-2-carbamate of formula I wherein A represents a multi-substituted alkyl group or aromatic ring.Type: GrantFiled: October 22, 2001Date of Patent: November 11, 2003Assignee: Angiogene Pharmaceuticals Ltd.Inventor: Peter David Davis
-
Publication number: 20030097020Abstract: The present invention provides a new and useful improvement in the process to manufacture a carboxylic acid salt, particularly an amino carboxylic acid salt, from a primary alcohol, particularly a primary aminoalcohol. The process of manufacturing amino carboxylic acid salts comprises contacting an aqueous solution of a primary aminoalcohol with a strong hydroxide base selected from the group consisting of an alkali metal hydroxide, an alkaline earth metal hydroxide, an ammonium hydroxide compound including a tetraalkyl ammonium hydroxide, or the like, in the presence of an effective amount of a catalyst. The catalyst comprises one or more of elements selected from the group consisting of copper, cobalt, nickel, and cadmium as well as optionally lesser amounts of chromium, titanium, niobium, tantalum, zirconium, vanadium, molybdenum, manganese, tungsten, cobalt, nickel, or mixtures thereof.Type: ApplicationFiled: May 3, 2000Publication date: May 22, 2003Inventors: Thaddeus S. Franczyk, William L. Moench
-
Publication number: 20020193609Abstract: Benzimidazole derivatives and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compounds. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.Type: ApplicationFiled: April 25, 2002Publication date: December 19, 2002Applicant: The Procter & Gamble CompanyInventors: Jame C. Quada, Joseph K. Agyin, James Berger Camden
-
Patent number: 6482843Abstract: Benzimidazole derivatives and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compounds. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.Type: GrantFiled: September 29, 2000Date of Patent: November 19, 2002Assignee: The Procter & Gamble CompanyInventors: James C. Quada, Jr., Joseph K. Agyin, James Berger Camden